Related Experiment Video
Updated: Sep 10, 2025

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
Published on: March 3, 2023
Clinical efficacy and cost effectiveness of SGLT2i in diabetic nephropathy: a large population-based study
Hsuan-Hui Wang1, Yi-Wen Chiu2, Cheng-Yin Chung3
1Department of Nursing, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Division of Nursing, Pingtung Hospital, Ministry of Health and Welfare, Taiwan; Department of Healthcare Administration and Medical Informatics, Kaohsiung Medical University, Kaohsiung, Taiwan.
Objective:
To evaluate the clinical efficacy and cost-effectiveness of SGLT2i versus non-use in routine care for diabetic nephropathy.
Methods:
A retrospective cohort study was conducted analyzing patients diagnosed with diabetic kidney disease at three medical centers in Taiwan between 2017 and 2023. Inverse probability of treatment weighting (IPTW) minimized selection bias. The maximum follow-up period for clinical outcomes was 5.9 years, with a median duration of 2.79 years. A Markov model with a 10-year horizon, 1-year cycle, and 3 % discount rate assessed cost-effectiveness from the healthcare payer perspective.
Results:
SGLT2i use was associated with statistically significant improvements in estimated glomerular filtration rate (eGFR) and hemoglobin A1c (HbA1c) compared to non-SGLT2i treatment (p < 0.05). Mean total cost per patient was $38,072 for the SGLT2i group and $26,567 for the non-SGLT2i group. The incremental quality-adjusted life years (QALYs) gain was 0.70, resulting in an incremental cost-effectiveness ratio (ICER) of $16,435.71/QALYs. This value was well below the established willingness-to-pay (WTP) threshold of $32,756, indicating favorable cost-effectiveness.
Conclusions:
Although SGLT2i demonstrate favorable clinical efficacy and cost-effectiveness, National Health Insurance reimbursement for their use in diabetic nephropathy remains pending, and the potential for genitourinary infections necessitates ongoing clinical vigilance.
More Related Videos
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
07:13Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Oral Hypoglycemic Agents: Glinides
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: Sulfonylureas